Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

37.63 +0.39 (+1.05%)
Streaming Delayed Price Updated: 10:15 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future ↗
Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock. 
Via Benzinga
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Soleno Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short ↗
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook. 
Via Benzinga
News headline image
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges ↗
The companies are working on treatments for a rare, genetic disease that can cause excessive hunger. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside ↗
Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR. 
Via Stocktwits
Topics Death
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe ↗
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal. 
Via Benzinga
News headline image
Soleno (SLNO) Q2 Revenue Jumps 30% ↗
Via The Motley Fool
News headline image
Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance ↗
Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch. 
Via Chartmill
Topics Earnings
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress ↗
Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February. 
Via Benzinga
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.